SCHEMBL681035

SCHEMBL681035

CS(=O)(=O)O.O=C(Nc1ccc(Oc2cc3cn[nH]c3cc2-c2ccncc2)c(F)c1)c1ccnn(-c2ccc(F)cc2)c1=O

nearest known ligand 0.55

Known targets — ChEMBL curated mechanism

ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AXL P30530 19/20 0.55
MET P08581 16/20 0.55
MERTK Q12866 18/20 0.54
TYRO3 Q06418 17/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12214704 0.96 AXL (0.59) AXLMETMERTKTYRO3
SCHEMBL2496266 0.89 AXL (0.55) AXLMETMERTKTYRO3
SCHEMBL680768 0.87 AXL (0.56) AXLMETMERTKTYRO3
SCHEMBL679258 0.84 AXL (0.60) AXLMETMERTKTYRO3
SCHEMBL680378 0.84 AXL (0.55) AXLMETMERTKTYRO3
SCHEMBL681088 0.84 MET (0.59) AXLMETMERTKTYRO3
SCHEMBL13531756 0.84 AXL (0.66) AXLMETMERTKTYRO3
SCHEMBL680267 0.82 AXL (0.57) AXLMETMERTKTYRO3
SCHEMBL680716 0.81 AXL (0.76) AXLMETMERTKTYRO3
SCHEMBL12190662 0.81 MET (0.62) AXLMETMERTKTYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC AXL 113/4885MET 1/4885MERTK 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.